GLGerd Luippold

Gerd Luippold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerd Luippold has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Bernd Mühlbauer

    University of Tübingen

    11 shared publications
  • Swetlana Schneider

    Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Tübingen, Germany

    6 shared publications
  • Peter Benöhr

    Center of Clinical Pharmacology

    5 shared publications
  • Hartmut Osswald

    Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Tübingen, Germany

    4 shared publications
  • Christine Piesch

    Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen

    3 shared publications
  • Maria Marto

    Laboratorium für Arzneimittelprüfung und Zulassungsberatung (LAZ), Prof. Dr. H. Hamacher

    2 shared publications

Latest Publications

  • Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats

    by Gerd Luippold, Martina Beilharz, Manfred Wehrmann, Liliane Unger, Gerhard Gross, Bernd Mühlbauer

    Dopamine D2-like receptors, including D2, D3, and D4 receptors, are involved in the regulation of glomerular hyperfiltration due to diabetes mellitus. These hemodynamic alterations represent a risk factor for the later development of diabetic nephropathy. The aim of the present study was to determine whether the D3 receptor subtype modulates the diabetes-induced increase in glomerular filtration rate (GFR) in rats. Renal function was studied in Sprague–Dawley rats 14 days after induction of a moderate diabetes mellitus (DM) by streptozotocin and in non-diabetic controls (CON). Rats were orally treated either with the peripherally acting, selective dopamine D3 receptor antagonist BSF 135170 (BSF, 10 mg/kg per day for 2 weeks) or with vehicle (VHC). Perfusion-fixed kidneys were used for estimation of glomerular volume. In conscious rats, which were treated with BSF, the DM-induced increase in fluid intake, urinary output, and renal sodium excretion was significantly less pronounced than in the vehicle group (DM-VHC). In the clearance experiments, GFR in CON was about 0.84±0.04 ml/min per 100 g body weight. The DM-VHC group presented a significant glomerular hyperfiltration (1.09±0.04 ml/min per 100 g body weight). Treatment with BSF significantly lowered GFR towards levels of CON. The estimated glomerular volume was 0.73±0.03×106 μm3 in the CON-VHC group and 0.86±0.04×106 μm3 in the DM-VHC animals. Interestingly, treatment with BSF decreased the glomerular volume in both groups. Irrespective of BSF treatment, kidney wet weight related to body weight was about 36% higher in DM animals compared with CON animals. We conclude that dopamine D3 receptors represent a target for the modulation of diabetes-induced glomerular hyperfiltration. Therefore, the results encourage the testing of the possible beneficial effects of long-term D3 receptor blockade on the development of diabetic nephropathy.


  • Blood Glucose Profiles in Diabetic Rodents Using Different Insulin Preparations

    by Swetlana Schneider, Renate Weber, Gerd Luippold

    The aim of the present study was to evaluate several long-acting insulin preparations for their ability to normalize the blood glucose profile of rats and mice with streptozocin-induced diabetes mellitus. The single injection of a long-acting zinc insulin (CAS 8049-62-5) suspension or insulin glargine (CAS 160337-95-1) in both species induced a steep to moderate fall in blood glucose concentration. Blood glucose was then normalized for 2-3 h, until 3 h after insulin injection blood glucose concentration tended towards levels before insulin application. In contrast, implants produced with a mixture of human insulin and palmitic acid micro-crystals normalized blood glucose profile over 24 h in both species at least 30 days after implantation. Therefore, these implants with a sustained release of insulin are suitable to control the blood glucose in diabetic rats and mice. Blutzuckerprofil diabetischer Nager unter Verwendung verschiedener Insulin-Präparationen Ziel der vorliegenden Studie war, verschiedene Langzeit-Insuline in ihrer Fähigkeit zur Normalisierung des Blutglukoseprofils von Ratten und Mäusen mit durch Streptozocin induziertem Diabetes mellitus zu beurteilen. Eine Einzelinjektion einer langwirkenden Zinkinsulin (CAS 8049-62-5)-Suspension bzw. von Insulin-Glargin (CAS 160337-95-1) induzierte eine steile bis mäßige Abnahme der Blutglukosekonzentration. Eine Normalisierung der Blutglukose wurde für 2-3 h erreicht, wobei 3 h nach der Insulininjektion die Blutglukosekonzentration in der Tendenz auf Werte vor der Insulingabe anstieg. Im Gegensatz dazu normalisierten Implantate, die aus einer Mischung von humanem Insulin und kristallisierter Palmitinsäure hergestellt wurden, das Blutglukoseprofil über 24 h bei beiden Tierarten und dies über mindestens 30 Tage im Anschluß an die Implantation. Somit sind die verwendeten Implantate, die eine anhaltende Freisetzung von Insulin aufweisen, zur Kontrolle der Blutglukose bei diabetischen Ratten und Mäusen über einen längeren Zeitraum geeignet.


  • Open Access

    Subapical Localization of the Dopamine D3 Receptor in Proximal Tubules of the Rat Kidney

    by Asja Nürnberger, Marcus Räbiger, Andreas Mack, Jorge Diaz, Pierre Sokoloff, Bernd Mühlbauer, Gerd Luippold

    The dopamine D3 receptor (D3R), intensively studied in neuroscience, also plays an important role in the regulation of renal and cardiovascular function. In contrast to functional findings, less information is available on its localization in the kidney. Neither RT-PCR studies nor radioligand binding assays are suitable to selectively determine the distribution of renal D3R at the level of cellular or even subcellular structures. We studied the renal D3R distribution in Sprague-Dawley rats by a polyclonal antiserum directed against an epitope in the third intracytoplasmic loop. D3R immunoreactivity was detected by indirect immunofluorescence and confocal laser scanning microscopy. D3R staining was confined to the renal cortex and occurred in proximal convoluted tubules near or in direct connection with the urinary pole of the glomeruli. The fluorescent spots were restricted to the subapical portion of the proximal tubular cells. Double staining with the F-actin marker phalloidin revealed a localization of the D3R below the brush border region. However, staining by anti-P1/p2-adaptins, recognizing clathrin-coated compartments, did not correspond to the distribution of the D3R signal. This is the first description of a D3R accumulation in a cytoplasmic pool in the kidney, probably corresponding to a recycling mechanism or storage compartment.


  • Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats

    by G. Luippold

    The increase in glomerular filtration rate (GFR) induced by amino acid infusion is attenuated in rats with chronic renal denervation. The aim of the present study was to investigate whether renal denervation abrogates glomerular hyperfiltration occurring in the early state of diabetes mellitus. Sprague-Dawley rats were subjected to bilateral renal denervation before induction of diabetes mellitus (DM) by streptozotocin. Clearance experiments were performed 2 weeks after onset of moderate DM. Glomerular volume was estimated following paraformaldehyde fixation in rat kidney slices from measurement of cross-sectional area of Bowman's capsule. GFR in non-diabetic rats with intact nerves (CON-INN) was 0.82+/-0.03 ml.min(-1).100 g(-1) body weight. Diabetic animals with innervated kidneys presented a significant glomerular hyperfiltration (1.13+/-0.03 ml.min(-1).100 g(-1) body weight), while renal denervation in diabetic rats lowered GFR towards levels of CON-INN (0.88+/-0.03 ml.min(-1).100 g(-1) body weight). Estimated glomerular volume amounted to 0.69+/-0.03.10(6) micro m(3) in the CON-INN group and was significantly higher in diabetic animals with intact renal nerves (0.86+/-0.04.10(6) microm(3)). Interestingly, renal denervation prevented the glomerular enlargement due to DM. Renal nerves appear to be significantly involved in the mediation of glomerular hyperfiltration in experimental DM. If the kidney is prevented from sympathetic nerve stimulation, structural changes due to early diabetic nephropathy, i.e. glomerular enlargement, are abolished.


  • Role of the renin-angiotensin system in the compensation of quinpirole-induced blood pressure decrease

    by Gerd Luippold, Alexander Max, Margitta Albinus, Hartmut Osswald, Bernd Mühlbauer

    The dopamine D2-like receptor agonist quinpirole has been reported to lower blood pressure. This effect appears to be mediated via activation of presynaptic D2-like receptors inhibiting the stimulated neural norepinephrine release. The aim of the present study was to investigate the role of renal nerves and the renin-angiotensin system (RAS) in the blood pressure lowering effect of quinpirole. Therefore, clearance experiments using different doses of quinpirole (0.3 to 100 µg/kg/min) were performed in thiopental-anesthetized rats with intact kidneys (INN) or 5 to 7 days after bilateral renal denervation (DNX). The functional involvement of the RAS in the blood pressure lowering effect of quinpirole was determined in rats pretreated with a subpressor dose of angiotensin II (10 µg/kg/min) or in rats pretreated with the angiotensin II (AT1) receptor antagonist losartan, in a subdepressor dose (10 µg/kg/min). Quinpirole dose-dependently decreased mean arterial blood pressure (MAP) by up to 29%. This blood pressure lowering effect of quinpirole was observed at lower doses in DNX rats when compared with INN animals (ED50: 0.98 µg/kg/min in DNX vs. 6.02 µg/kg/min in INN animals). Quinpirole in a dose of 3 µg/kg/min, which did not affect MAP in vehicle treated INN rats, significantly reduced MAP in rats with losartan pretreatment. In DNX rats pretreated with angiotensin II the MAP-response to the infusion of 3 µg/kg/min quinpirole was clearly attenuated in comparison with untreated DNX animals. Our data show that stimulation of dopamine D2-like receptors dose-dependently decreased blood pressure, which was potentiated by both interruption of the renal innervation and AT1 receptor blockade, while exogenous ANG II restored the enhancement of the blood pressure response to quinpirole. We conclude that the increased vasodilatory effect of quinpirole after renal denervation might depend on a decreased activity of the RAS.


  • Open Access

    Dopamine D3 Receptor mRNA and Renal Response to D3 Receptor Activation in Spontaneously Hypertensive Rats

    by Gerd Luippold, Christine Piesch, Hartmut Osswald, Bernd Mühlbauer

    Defective dopamine receptors may be involved in the development of hypertension. Recently, it has been shown that gene expression and function of the renal dopamine D3 receptor is impaired in salt-sensitive Dahl rats, a model of salt-dependent hypertension. Here, the functional response to D3 receptor activation was investigated in spontaneously hypertensive rats (SHR) and their normotensive Wistar-Kyoto rats (WKY). In addition, expression of the D3 receptor gene was studied in both rat strains. In clearance experiments, Ringer solution was infused at baseline in thiopental-anesthetized SHR and WKY (each n =8), followed by an infusion of R(+)-7-hydroxy-dipropylaminotetralin (DPAT), a specific D3 receptor agonist. DPAT was infused in two consecutive doses of 0.01 and 0.1μg/min per kg body weight. During the entire experiment mean arterial blood pressure was significantly higher (1.5-fold) in adult SHR when compared to age-matched WKY. In both groups DPAT infusion induced a similar dose-dependent increase in urinary flow rate and sodium excretion by a maximum of 2.3-fold and 3.5-fold, respectively. DPAT also increased the glomerular filtration rate in both SHR and WKY. Reverse transcription-polymerase chain reaction studies of whole kidney samples showed no significant differences between young prehypertensive and adult hypertensive SHR when compared to age-matched normotensive WKY. In summary, pharmacological dopamine D3 receptor activation induces a uniform renal response in SHR and WKY. Together with the similar D3 receptor gene expression in both rat strains, which is independent of age or blood pressure levels, the results do not support the notion that the dopamine D3 receptor system is involved in the pathogenesis of hypertension in the SHR model. (Hypertens Res 2003; 26: 855-861)


  • Age dependency of renal function in CD-1 mice

    by Gerd Luippold, Bärbel Pech, Swetlana Schneider, Hartmut Osswald, Bernd Mühlbauer

    Renal function was studied in mice of different ages. In metabolic cage experiments, the renal electrolyte excretion was similar in young ( n = 8; 5- to 7-wk-old) and adult ( n = 6; 20- to 22-wk-old) CD-1 (ICR) BR mice, whereas spontaneous drinking volume and urinary flow rate were significantly higher in the adult compared with the young mice. Subsequently, the renal functional reserve was investigated by amino acid (AA) infusion (10%) in anesthetized young ( n = 8) and adult ( n= 6) mice. Because the body weight of adult mice was significantly higher than that of young animals, one group of adult mice ( n = 8) received 12.5% AA to ensure that the dose of AA related to body weight was similar in both groups. Young animals constantly infused with Ringer solution served as time controls ( n = 8). Glomerular filtration rate (GFR) at baseline was similar in each group. Because of AA, GFR significantly increased in young mice but not in both groups of adult animals, whereas in time controls GFR remained constant. Urinary flow rate and sodium excretion were elevated by AA in young and adult mice. We conclude that in CD-1 mice the first signs of age-related changes in kidney function concern alterations in renal hemodynamics, whereas renal tubular function appears to be preserved.


  • Pharmacokinetics of Two Oral Prednisolone Tablet Formulations in Healthy Volunteers

    by Gerd Luippold, Swetlana Schneider, Maria Marto, Peter Benöhr, Bernd Mühlbauer

    Two prednisolone (CAS 50-24-8) formulations (Prednisolon 50 mg Ferring tablets as the test preparation and tablets of a reference preparation) were investigated in 13 healthy volunteers in order to prove bioequlvalence between these preparations. A single oral dose of 50 mg was given using a randomized, two-way cross-over design with a wash-out period of one week. Blood samples for determination of prednisolone plasma concentrations were collected up to 15 h following drug administration. Additionally, in vitro tests were performed with tablets from the same lots to determine dissolution characteristics. Prednisolone concentrations were measured by means of validated HPLC with UV-detection. Maximum concentrations (Cmax) of 1020.9 ± 57.8 and 1053.3 ± 55.7 ng/ml were achieved for the test and the reference preparation, respectively. The AUC0–∞ was 212.2 ± 13.2 µg • min/ml (test preparation) and 222.2 ± 14.3 µg • min/ml (reference preparation). The 90 % confidence intervals of the test to reference ratios were within the range of 80–125 % with 97.8-101.3 % for Cmax and 98.1-100.4 % for AUC0–∞. The time to reach maximum plasma concentration (tmax) tended to be lower (-25 %) in the test (39.6 ± 6.4 min) as compared to the reference preparation (52.8 ± 9.0 min). Interestingly, this difference correlated well with the observation of a more rapid dissolution rate of the test preparation by some 10 min. Both prednisolone formulations were well tolerated. Based on the results obtained in this study, (1) bloequiva-lence between the test and the reference preparation was clearly demonstrated and (2) a positive correlation between dissolution rate observed in vitro and tmax as measured in vivo was found. Bioverfügbarkeit zweier oraler Prednlso-lon-Tablettenzubereltungen bei gesunden Probanden Zwei Prednisolon (CAS 50-24-8)-Zubereitungen (Prednisolon 50 mg Ferring Tabletten als Testpräparat und Tabletten eines Referenzpräparates) wurden an 13 gesunden Probanden auf Bioäquivalenz getestet. Einzeldosen von 50 mg wurden nach einem randomislerten Zweiweg-Cross-over-Design verabreicht; die Aus-wasch-Periode betrug eine Woche. Blutproben zur Bestimmung der Predniso-lon-Konzentration im Plasma wurden bis 15 h nach Medikation entnommen. Zusätzlich wurden In-vitro-Tests mit Tabletten der gleichen Charge zur Bestimmung der Freisetzungscharakteristika durchgeführt. Prednisolon-Konzentrationen wurden mittels validierter HPLC durch UV-Detektion gemessen. Die maximalen Plasmakonzentrationen (Cmax) betrugen 1020.9 ± 57.8 für das Test- und 1053.3 ± 55.7 ng/ml für das Referenzpräparat. Die AUC0–∞ betrug 212.2 ± 13.2 µg • min/ ml (Testpräparat) und 222.2 ± 14.3 µg • min/ml (Referenzpräparat). Die 90 % Konfidenzintervalle der Test/Referenz-Quotienten lagen mit 97.8-101.3 % für Cmax und 98.1-100.4 % für die AUC 0–t innerhalb des 80–125 % Bereiches. Die Zeit bis zum Erreichen der maximalen Plasmakonzentration (tmax) war bei dem Testpräparat (39.6 ± 6.4 min) um 25 % niedriger im Vergleich zum Referenzpräparat (52.8 ± 9.0 min). Dieser Unterschied korrelierte gut mit einer um etwa 10 minschnelleren Freisetzung des Testpräparates. Beide Prednisolon Zubereitungen wurden gut vertragen. Die Studie wies die Bioäquivalenz der beiden getesteten Präparate nach. Außerdem wurde eine positive Korrelation zwischen in vitro bestimmter Freisetzungsrate und der in vivo erhobenen tmax gefunden.


  • Bioequivalence of Different Prednisolone Tablet Formulations

    by Gerd Luippold, Peter Benöhr, Swetlana Schneider, Maria Marto, Bernd Mühlbauer

    The relative bioavailability of different prednisolone (CAS 50-24-8) tablet formulations (Prednisolon Ferring 2, 5, and 20 mg) was investigated in comparison to a reference formulation. The study was performed in a GCP/ICH-conform manner using a randomized cross-over design in 13 healthy volunteers. With respect to the pharmacokinetic parameters Cmax (maximal prednisolone concentration), AUC0 -12 h (area under the concentration-time curve until 12 h after drug intake), AUC0–∞ (area under the concentration-time curve until infinity), and t1/2 (elimination half-life time), 10 × 2 mg prednisolone tablets did not show any relevant differences as compared to the reference (1 × 20 mg) meaning that the 90 % confidence intervals were within the given 0.80-1.25 limits for the decision of bioequivalence. Although not statistically significant, tmax (time to reach the maximal prednisolone plasma concentration) was 11 min shorter regarding the test preparation as compared to the reference. The pharmacokinetic parameters of 4 × 5 prednisolone tablets were also well in accordance with the reference. The most important parameters Cmax, AUC and t1/2 were within the defined limits for the acceptance of bioequivalence and, in addition, tmax did not show any significant differences. The 20 mg prednisolone tablet formulation showed almost identical parameters of Cmax, AUC, t1/2 und tmax in comparison to the reference substance. Taken together, the results of the bioavailability parameters indicate the bioequivalence of the three prednisolone test preparations as compared to the reference. Untersuchung zur Bioäquivalenz von verschiedenen Prednisolon-Tabletten-zubereitungen An 13 gesunden Probanden wurde in einer GCP/ICH-konform durchgeführten, randomisierten Cross-over-Studie die relative Bioverfügbarkeit von verschiedenen Prednisolon (CAS 50-24-8)-Tabletten-zubereitungen (Prednisolon Ferring 2, 5 und 20 mg) im Vergleich zu einem Referenzpräparat untersucht. Die 2-mg-Pred-nisolon-Formulierung zeigte dosiskorrigiert bezüglich der pharmakokinetischen Parameter Cmax (maximale Prednisolon-Konzentration), AUC0–12 h (Fläche unter der Kurve bis 12 h nach der Tabletteneinnahme), AUC0–∞ (Fläche unter der Kurve bis unendlich) und t1/2 (Eliminationshalb-wertszeit) gegenüber dem Referenzpräpa-rat keine Unterschiede, d. h. die üblichen Vertrauensbereiche für eine Äquivalenzentscheidung (90 % Konfidenzintervall im Bereich 0,80 bis 1,25) wurden nicht überschritten. Obgleich statistisch nicht signifikant, war die mittlere tmax (Zeit bis zum Erreichen der maximalen Prednisolon-Plasmakonzentration) für das Prüfpräparat um 11 min kürzer als für die Re-ferenz. Die Pharmakokinetik der 5-mg Prednisolon-Tablettenformulierung stimmte mit der des Referenzpräparates gut überein. Die wichtigsten Parameter Cmax, AUC und t1/2 befanden sich dosiskorrigiert innerhalb der definierten Akzeptanzgrenzen für die Bioäquivalenz. Die tmax-Werte unterschieden sich nicht signifikant. Die 20-mg-Prednisolon-Tabletten wiesen fast identische Parameter für Cmax, AUC, t1/2 und tmax im Vergleich zu dem Referenzpräparat auf. Insgesamt sind die drei Prednisolon-Prüfpräparate und das Referenzpräparat pharmakokinetisch als bioäquivalent zu bewerten.